Funding for this research was provided by:
National Institutes of Health (R01-HG009937, R01-MH118349, P01-CA142538, P30-ES010126, P01-CA151135, P50-CA05822, U01-CA179715)
Received: 4 October 2019
Accepted: 21 January 2020
First Online: 20 February 2020
Ethics approval and consent to participate
: This study was approved by the Office of Human Research Ethics at the University of North Carolina at Chapel Hill, and written informed consent was obtained from each participant. All experimental methods abided by the Helsinki Declaration.
: Not applicable.
: C.M.P. is an equity stockholder in and consultant for BioClassifier LLC; C.M.P. is also listed as an inventor on patent applications on the Breast PAM50 Subtyping assay. The other authors declare that they have no competing interests.